Vol. 26/No. 2

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.

Nirav N. Shah, MD, MSHP, and Michael T. Tees, MD, MPH, detail BTK degraders such as NX-5948 under investigation in the CLL/SLL space.

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Maurie Markman, MD, discusses the differences between prognostic vs predictive factors and their clinical utility in oncology practice.

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.